At Nanostics our focus is on the development of novel and non-invasive diagnostic tests to help better manage disease.

Our core technology is in development to be able to diagnose disease from a single drop of blood by combining a highly sensitive extracellular vesicle detection platform with advanced machine learning algorithms.

The Challenge:

Each drop of blood carries billions of messages with critical information.


This wealth of information is transmitted throughout our bodies via the bloodstream using a complex extracellular vesicle messaging system.


It is a monumental challenge to detect and decipher these messages to better diagnose and manage the treatment of disease.

Our Solution:

Our core technology can read and decipher information from millions of particles in a single drop of blood with unprecedented accuracy.


Our non-invasive and cost-effective technology combines advanced flow cytometry with sophisticated machine learning algorithms and is currently in developmental trials to provide more timely and accurate information that can be used to better manage disease in the near future.

Our novel technology is applicable to a wide range of diseases, including prostate, brain,
pancreatic and blood cancers
as well as cardiovascular and neuro-degenerative diseases.

Learn More

Our lead product currently in development, ClarityDx Prostate, is set to become the most accurate diagnostic test to diagnose aggressive prostate cancer and is positioned to emerge as the world’s leading diagnostic tool to transform the management of prostate cancer.

Learn More

Our success would not be possible without the support of our many Canadian and internationalcollaborators, funders and partners.